1. Home
  2. ACCO vs NGEN Comparison

ACCO vs NGEN Comparison

Compare ACCO & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acco Brands Corporation

ACCO

Acco Brands Corporation

N/A

Current Price

$3.51

Market Cap

373.2M

ML Signal

N/A

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$3.95

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACCO
NGEN
Founded
1893
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Publishing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
373.2M
317.6M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
ACCO
NGEN
Price
$3.51
$3.95
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
608.9K
93.7K
Earning Date
06-10-2026
01-01-0001
Dividend Yield
8.26%
N/A
EPS Growth
141.51
N/A
EPS
0.44
N/A
Revenue
$1,524,700,000.00
N/A
Revenue This Year
$5.79
N/A
Revenue Next Year
$4.84
N/A
P/E Ratio
$8.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.20
$3.73
52 Week High
$4.82
$5.93

Technical Indicators

Market Signals
Indicator
ACCO
NGEN
Relative Strength Index (RSI) 26.37 40.95
Support Level $3.34 $3.76
Resistance Level $3.86 $4.44
Average True Range (ATR) 0.13 0.26
MACD -0.07 0.03
Stochastic Oscillator 4.09 28.57

Price Performance

Historical Comparison
ACCO
NGEN

About ACCO Acco Brands Corporation

ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: